Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

UN Chief Warns of 'Great Fracture' Among Global Powers: https://g.foolcdn.com/editorial/images/748322/featured-daily-upside-image.png
UN Chief Warns of 'Great Fracture' Among Global Powers

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

As the United

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost: https://g.foolcdn.com/editorial/images/747922/business-person-giving-a-thumbs-up.jpg
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost: https://g.foolcdn.com/editorial/images/747922/business-person-giving-a-thumbs-up.jpg
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost: https://g.foolcdn.com/editorial/images/747922/business-person-giving-a-thumbs-up.jpg
This Recent FDA Approval Could Give Regeneron's Top Line a Big Boost

Regeneron Pharmaceuticals (NASDAQ: REGN) has made for a fantastic growth story over the years. From just over $2 billion in revenue in 2013, the company's top line rose to more than $12 billion last

With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?: https://g.foolcdn.com/editorial/images/747834/tired-_-worried-healthcare-worker-in-hospital-2.jpg
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?

The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech

With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?: https://g.foolcdn.com/editorial/images/747834/tired-_-worried-healthcare-worker-in-hospital-2.jpg
With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock?

The Food and Drug Administration (FDA) just approved the updated Omicron-adapted COVID-19 booster shots from Moderna (NASDAQ: MRNA) and the COVID-19 booster that Pfizer (NYSE: PFE) and BioNTech

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio: https://g.foolcdn.com/editorial/images/747686/three-scientists-work-in-laboratory-with-one-looking-down-a-microscope.jpg
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio: https://g.foolcdn.com/editorial/images/747686/three-scientists-work-in-laboratory-with-one-looking-down-a-microscope.jpg
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio: https://g.foolcdn.com/editorial/images/747686/three-scientists-work-in-laboratory-with-one-looking-down-a-microscope.jpg
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio

CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Pfizer Stock: Bear vs. Bull: https://g.foolcdn.com/editorial/images/747854/two-investors-put-sticky-notes-on-glass-wall.jpg
Pfizer Stock: Bear vs. Bull

Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be

Pfizer Stock: Bear vs. Bull: https://g.foolcdn.com/editorial/images/747854/two-investors-put-sticky-notes-on-glass-wall.jpg
Pfizer Stock: Bear vs. Bull

Pfizer (NYSE: PFE) is a stock that everyone's familiar with, but that doesn't mean that everyone agrees you should buy it. While its promise of steady returns and a decent dividend might be

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know: https://g.foolcdn.com/editorial/images/747681/scientist-gestures-to-diagram-on-whiteboard.jpg
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know

Other than running out of money, what economic risk do Intellia Therapeutics, (NASDAQ: NTLA) CRISPR Therapeutics, (NASDAQ: CRSP) Bluebird Bio, (NASDAQ: BLUE) and a bunch of other cutting-edge

You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10: https://g.foolcdn.com/editorial/images/747989/gettyimages-1135625573.jpg
You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10

It's best not to go all in on high-risk stocks, but that doesn't mean you should avoid them entirely. If you can tolerate some risk, certain players could make a good addition to a diversified

Why Shares of Scilex Are Dropping Monday: https://g.foolcdn.com/editorial/images/748024/2valuestocks.jpg
Why Shares of Scilex Are Dropping Monday

Shares of Scilex (NASDAQ: SCLX) were down more than 14% as of 1 p.m. ET on Monday, despite the company announcing positive phase 2 trial results for its non-opioid pain therapy SP-103. The healthcar

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Agriculture Titans Are In a Head-to-Head Battle for America's Soy Farmers: https://g.foolcdn.com/editorial/images/747968/featured-daily-upside-image.jpeg
Agriculture Titans Are In a Head-to-Head Battle for America's Soy Farmers

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The US harvests

Agriculture Titans Are In a Head-to-Head Battle for America's Soy Farmers: https://g.foolcdn.com/editorial/images/747968/featured-daily-upside-image.jpeg
Agriculture Titans Are In a Head-to-Head Battle for America's Soy Farmers

For more crisp and insightful business and economic news, subscribe to The Daily Upside newsletter It's completely free and we guarantee you'll learn something new every day.

The US harvests

Why Shares of ImmunityBio Jumped This Week: https://g.foolcdn.com/editorial/images/747799/nurses-station-in-hospital.jpg
Why Shares of ImmunityBio Jumped This Week

Shares of ImmunityBio (NASDAQ: IBRX) were up more than 30% for the week as of 10 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech's stock

2 Top Biotech Stocks Defying the Bear Market: https://g.foolcdn.com/editorial/images/747410/cancer-patient-flexing-muscle.jpg
2 Top Biotech Stocks Defying the Bear Market

Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis

2 Dividend Kings to Buy on the Dip and Hold Forever: https://g.foolcdn.com/editorial/images/747350/doctor-and-patient-in-a-hospital-room.jpg
2 Dividend Kings to Buy on the Dip and Hold Forever

The elite club of Dividend Kings arguably stands out as the market's most prestigious group of dividend payers. Companies must have raised their payouts for at least 50 consecutive years to join, a

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Could Abbott Laboratories Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/747360/two-couples-on-a-yacht.jpg
Could Abbott Laboratories Stock Help You Become a Millionaire?

Abbott Laboratories (NYSE: ABT) is a leading healthcare company with a global presence. It has a diverse business with four key segments: established pharmaceuticals, diagnostics, nutrition, and

Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday: https://g.foolcdn.com/editorial/images/747734/two-people-seated-at-a-lab-desk-featuring-a-pc-screen-and-microscope.jpg
Why Aclaris Therapeutics Stock Soared Nearly 6% on Thursday

Aclaris Therapeutics (NASDAQ: ACRS) had a fine Thursday, at least as far as its stock was concerned. The biotech's shares enjoyed a nearly 6% lift in price, thanks largely to a generous price-target